BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-94@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Veradermics\, Inc. — VDPHL01 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Safety and Efficacy of VDPHL01 in M
 ales With AGA.\nSource: https://clinicaltrials.gov/study/NCT06972264\nhttp
 s://catalystbrief.girapphe.com/e/94?lang=en\nNot investment advice. Dates 
 may change.
URL:https://catalystbrief.girapphe.com/e/94?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
